Andrew Sheets: Even in a Crisis, the Cycle Still Matters
Investment strategies tied to the business cycle are still relevant, especially as our key internal indicator shows the cycle has moved into a new phase. Andrew Sheets, Chief Cross-Asset Strategist, m...
24 Apr 20203min
Special Episode, Part 2: How Much Stimulus Is Enough?
Congress has readied more funds to support U.S. businesses and households in order to shorten the pandemic-induced downturn. How far will they go? Chief U.S. Economist Ellen Zentner and Head of Public...
23 Apr 20206min
Special Episode: How Much Stimulus Is Enough?
Congress has readied more funds to support U.S. businesses and households in order to shorten the pandemic-induced downturn. How far will they go? Chief U.S. Economist Ellen Zentner and Head of Public...
22 Apr 20208min
Mike Wilson: Equities Position for America’s Grand Reopening
Although it remains to be seen how fast the U.S. can “re-open,” in the near term, markets may be betting on an economy that will normalize faster than feared.
20 Apr 20203min
Andrew Sheets: Why OPEC May Be Rethinking Its Strategy
The steep decline in oil prices is a fascinating story of demand, supply and even game theory. But Chief Cross-Asset Strategist Andrew Sheets says that story could reverse next year.
17 Apr 20203min
Reza Moghadam: Emerging-Market Economies Prepare for COVID-19
Emerging markets recovered quickly from the 2008 financial crisis, but could a more challenging backdrop in 2020 mean a different outcome this time? Insights from Chief Economic Adviser Reza Moghadam.
16 Apr 20204min
Michael Zezas: Has the Fed Ignited Muni Bond Markets?
For investors in municipal bonds, the Fed’s recent creation of the Municipal Liquidity Facility and Mainstreet Lending Facility are a key positive. Head of Municipal Strategy Michael Zezas explains wh...
15 Apr 20202min
Special Episode, Part 2: Coronavirus - Building Models to Rebuild Economies
When do we return to work? The market reaction? The drug pipeline? Chief Cross-Asset Strategist Andrew Sheets and Head Biotech Equity Analyst Matthew Harrison continue their discussion on the impact o...
14 Apr 202010min
